EGFR and non-small cell lung carcinoma: To investigate whether C9 and CsA affect the proliferation of NSCLC CSCs, CSCs derived from four EGFR-wild-type (A549 and NCI-H1299) or -mutant (NCI-H1650 and HCC827) NSCLC cell lines were treated with C9 or CsA at various concentrations (0–100 μM) for 4 days.